AstraZeneca's Nexium: Think Globally, Act Locally
Executive Summary
A combination of successful pricing and marketing tactics in competitive European markets such as Germany have helped AztraZeneca's blockbuster anti-ulcer franchise weather the generic storm. But the US could tell a different story.
You may also be interested in...
AstraZeneca: Bridging the Prilosec Earnings Gap
AstraZeneca appears to have navigated the integration process without much of the turmoil seen in other mergers. As part of that integration, the company created a new, centralized sales and marketing infrastructure intended to transform two mid-size European companies into a commercial global power. That new organization will soon confront the company's most immediate challenge: dealing with the genericization of the world's biggest drug, Prilosec. Whether AstraZeneca can meet that challenge will turn largely on the extent to which two late-stage drug candidates, Nexium and Crestor, can fill the Prilosec void. They'll require a commercialization effort far beyond that attempted by the former Astra or Zeneca.
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
CNS IPOs Follow Broad Industry Trends
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.